155 related articles for article (PubMed ID: 35276437)
21. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Results of Bilateral Lung Transplantation in Patients With End-Stage Pulmonary Lymphangioleiomyomatosis.
Salman J; Ius F; Sommer W; Siemeni T; Fleissner F; Alhadidi H; Kugler C; Avsar M; Haverich A; Warnecke G; Tudorache I; Kuhn C
Prog Transplant; 2019 Jun; 29(2):115-121. PubMed ID: 31084354
[TBL] [Abstract][Full Text] [Related]
23. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
24. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.
Almoosa KF; Ryu JH; Mendez J; Huggins JT; Young LR; Sullivan EJ; Maurer J; McCormack FX; Sahn SA
Chest; 2006 May; 129(5):1274-81. PubMed ID: 16685019
[TBL] [Abstract][Full Text] [Related]
25. Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation.
Zaki KS; Aryan Z; Mehta AC; Akindipe O; Budev M
World J Transplant; 2016 Mar; 6(1):249-54. PubMed ID: 27011924
[TBL] [Abstract][Full Text] [Related]
26. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis.
Kpodonu J; Massad MG; Chaer RA; Caines A; Evans A; Snow NJ; Geha AS
J Heart Lung Transplant; 2005 Sep; 24(9):1247-53. PubMed ID: 16143241
[TBL] [Abstract][Full Text] [Related]
27. Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis.
Bottolo L; Miller S; Johnson SR
Thorax; 2020 Aug; 75(8):679-688. PubMed ID: 32467337
[TBL] [Abstract][Full Text] [Related]
28. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
[TBL] [Abstract][Full Text] [Related]
30. Acute constrictive pericarditis after lung transplantation for lymphangioleiomyomatosis.
Billings ME; Mulligan M; Raghu G;
J Heart Lung Transplant; 2009 Jan; 28(1):110-3. PubMed ID: 19134542
[TBL] [Abstract][Full Text] [Related]
31. Lymphangioleiomyomatosis: New Treatment Perspectives.
Radzikowska E
Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
[TBL] [Abstract][Full Text] [Related]
32. Connectivity Map Analysis of a Single-Cell RNA-Sequencing -Derived Transcriptional Signature of mTOR Signaling.
Al Mahi N; Zhang EY; Sherman S; Yu JJ; Medvedovic M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922083
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
34. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
35. mTOR signaling in lymphangioleiomyomatosis.
Kristof AS
Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
[TBL] [Abstract][Full Text] [Related]
36. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
38. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
39. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.
Courtwright AM; Goldberg HJ; Henske EP; El-Chemaly S
Eur Respir Rev; 2017 Jan; 26(143):. PubMed ID: 28096282
[TBL] [Abstract][Full Text] [Related]
40. Lymphangioleiomyomatosis and mTOR inhibitors in real world-a narrative review.
Park S; Lee EJ
J Thorac Dis; 2023 Nov; 15(11):6333-6344. PubMed ID: 38090328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
